Table 3.

In Vitro Potency and Hypoxia Cytotoxicity Ratio (HCR) of the CA4 and CA1 BAPCs in the A549 Human Cancer Cell Line

compound	GI50 [oxic]a,b (μM)±SEM	GI50 [anoxic]a,b (μM)±SEM	HCR
RB6145	>89	24±6.7	>3.7
Tirapazamine	63±5.7	6.8±0.39	9.2
29 (CA1)	1.2±0.48	0.82±0.12	n/ac
42 (CA4)	0.0047±0.00021	0.0061±0.00048	n/ac
20	0.065±0.0030	0.19±0.015	n/ac
21	0.063±0.0087	0.046±0.0047	n/ac
22	0.44±0.022	0.52±0.060	0.85
23	4.6±0.14	3.3±0.36	1.4
24	1.9±0.66	0.30±0.047	6.3
25	2.9±0.22	1.2±0.20	2.4
26	1.5±0.39	0.49±0.033	3.1
35	0.046±0.0037	0.033±0.0012	1.4
36	0.55±0.025	0.72±0.17	0.76
37	0.17±0.040	0.28±0.082	0.61
38	0.18±0.061	0.26±0.077	0.69
39	0.32±0.014	0.69±0.031	0.46
40	0.31±0.035	0.051±0.0041	6.1
41	6.0±2.4	0.48±0.054	12.5
43	0.11±0.031	0.032±0.0073	3.4
44	0.15±0.027	0.038±0.0059	4.0
45	2.2±0.64	0.053±0.0088	41.5

^aAverage of n ≥ 3 independent determinations

^bIncubation involved 4 h (oxic or anoxic) followed by 48 h oxic exposure

^cn/a (not applicable)